TSBX vs. ENTX, GNTA, LENZ, CDTX, IKNA, ALGS, AVRO, ELUT, TIL, and DTIL
Should you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Entera Bio (ENTX), Genenta Science (GNTA), LENZ Therapeutics (LENZ), Cidara Therapeutics (CDTX), Ikena Oncology (IKNA), Aligos Therapeutics (ALGS), AVROBIO (AVRO), Elutia (ELUT), Instil Bio (TIL), and Precision BioSciences (DTIL). These companies are all part of the "biological products, except diagnostic" industry.
Turnstone Biologics (NASDAQ:TSBX) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.
In the previous week, Turnstone Biologics had 2 more articles in the media than Entera Bio. MarketBeat recorded 2 mentions for Turnstone Biologics and 0 mentions for Entera Bio. Turnstone Biologics' average media sentiment score of 0.30 beat Entera Bio's score of 0.00 indicating that Turnstone Biologics is being referred to more favorably in the media.
Entera Bio has lower revenue, but higher earnings than Turnstone Biologics.
Turnstone Biologics' return on equity of 0.00% beat Entera Bio's return on equity.
Turnstone Biologics presently has a consensus target price of $19.00, indicating a potential upside of 495.61%. Entera Bio has a consensus target price of $10.00, indicating a potential upside of 318.41%. Given Turnstone Biologics' higher possible upside, analysts clearly believe Turnstone Biologics is more favorable than Entera Bio.
52.5% of Turnstone Biologics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 8.9% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Entera Bio received 171 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 66.80% of users gave Entera Bio an outperform vote while only 50.00% of users gave Turnstone Biologics an outperform vote.
Summary
Turnstone Biologics beats Entera Bio on 8 of the 13 factors compared between the two stocks.
Get Turnstone Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Turnstone Biologics Competitors List
Related Companies and Tools
